GLP-1 response varies meaningfully across patients variants in GIPR, FTO, and MC4R, and TCF7L2 are associated with measurably different response patterns to semaglutide and tirzepatide
Novo Nordisks Peter Johannsen, MD, highlighted the biological signals observed and acknowledged the clinical limitations: subgroup analyses did not reveal meaningful benefit, and any potential responder group would be very small
Simplistically, GLP-1s like Ozempic or Mounjaro are appetite suppressants
Under experimentally induced oxidative stress conditions using hydrogen peroxide, BPC 157 appeared to support fibroblast survival relative to untreated controls
However, not everyone is a candidate for these medications, and others might prefer to explore alternatives
There have been reports on the relationship between GLP-1 medications and dementia, with some finding a reduced risk of dementia following a GLP-1 medication prescription 1 and others indicating variability depending on how these medications cross the blood-brain barrier